Weimin Mao

机构：Guangxi Medical University, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, First Affiliated Hospital of GuangXi Medical University, Hangzhou Cancer Hospital

发表论文 51 篇 · 总被引 935 次 · h-index 15

代表论文

• Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial (2021 · The Lancet Respiratory Medicine · 被引 193)
• A Novel Inflammation-Based Prognostic Score, the C-Reactive Protein/Albumin Ratio Predicts the Prognosis of Patients with Operable Esophageal Squamous Cell Carcinoma (2015 · PLoS ONE · 被引 127)
• The long noncoding RNA CASC9 regulates migration and invasion in esophageal cancer (2016 · Cancer Medicine · 被引 100)
• Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes (2021 · Nature Communications · 被引 77)
• Cell-Cycle and DNA-Damage Response Pathway Is Involved in Leptomeningeal Metastasis of Non–Small Cell Lung Cancer (2017 · Clinical Cancer Research · 被引 67)
• Cell-Free RNA Content in Peripheral Blood as Potential Biomarkers for Detecting Circulating Tumor Cells in Non-Small Cell Lung Carcinoma (2016 · International Journal of Molecular Sciences · 被引 19)